Cardiotoxicity is a leading cause of safety-related drug withdrawals, which presents a need to screen for toxic events early in the drug discovery process. The most common testing done for the cardiotoxicity of drugs uses in vivo animal studies and in vitro human ether-a-go-go related gene (hERG) assay. Animal studies and hERG assays inappropriately predict cardiotoxicity in humans leading to advancements in in vitro methodologies and iPSC models. Compounds that exert cardiovascular toxicity can cause severe adverse effects such as arrhythmia, myocardium structural damage, or death. Late-stage failures can be avoided by comprehensively screening compounds to identify cardiotoxic pathways that may interfere with cardiac function or physiology.